Astellas, Amgen to pay $124.75M for False Claims Act violations
By 
Jaclyn Jaeger2019-04-26T20:03:00
Pharmaceutical companies Astellas and Amgen will pay a total of $124.75 million to resolve allegations that they violated the False Claims Act by illegally paying the Medicare co-pays for their own high-priced drugs.
More from Regulatory Enforcement
-
News BriefDelta to pay $8.1 million over False Claims Act violations tied to pandemic aid
Delta Air Lines agreed to pay $8.1 million over allegations it violated the False Claims Act by exceeding employee compensation limits it agreed to when taking federal pandemic aid money.
-
News BriefDOJ and CFTC close investigations into crypto betting platform Polymarket, report says
The U.S. Department of Justice (DOJ) and the Commodity Futures Trading Commission (CFTC) reportedly ended two investigations into Polymarket, a popular online crypto betting service that calls itself a “prediction market.” The move continues the Trump administration’s pro-crypt agenda.
-
News BriefFTC fines telehealth firm over deceptive weight-loss claims and fake reviews
The U.S. Federal Trade Commission said it has settled with telemedicine service Southern Health Solutions, Inc. over allegations the company used deceptive pricing and weight-loss claims, along with fake reviews and testimonials, to sell its weight-loss programs.